Ganciclovir
- Generic Name
- Ganciclovir
- Brand Names
- Cytovene, Zirgan
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N5O4
- CAS Number
- 82410-32-0
- Unique Ingredient Identifier
- P9G3CKZ4P5
- Background
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
- Indication
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
- Associated Conditions
- CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
- Conditions
- Graft Versus Host DiseaseNonneoplastic Condition
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- University Hospital Birmingham
- Target Recruit Count
- 78
- Registration Number
- NCT00986557
- Locations
- 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers
- Conditions
- Ovarian Cancer
- Interventions
- Genetic: Ad5.SSTR/TK.RGD
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 11
- Registration Number
- NCT00964756
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
- Conditions
- Viraemia
- Interventions
- Drug: Stop treatment when 2 levels CMV PCR <3,000 copies / mlOther: Monitor (Treatment starts when CMV PCR >3,000 copies / ml)Other: Monitor (Treatment stops CMV PCR <200 copies / ml x2)
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- University College, London
- Target Recruit Count
- 165
- Registration Number
- NCT00947141
- Locations
- 🇬🇧
Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond Street, London, United Kingdom
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
- Conditions
- EBV LymphomasLympho-proliferative Diseases
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00917826
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmChronic Myeloproliferative DisordersMyelodysplastic SyndromesLymphomaLeukemiaNonneoplastic ConditionMyelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00716911
Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
- Conditions
- MDSMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableLeukemiaLymphomaMultiple MyelomaMyelodysplastic/Myeloproliferative Diseases
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 61
- Registration Number
- NCT00530218
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 307
- Registration Number
- NCT00497796
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
- Conditions
- Cytomegalovirus Infections
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 325
- Registration Number
- NCT00431353
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
- Conditions
- DNA Virus InfectionHerpesviridae InfectionsCytomegalovirus Infection
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Lower Saxony Center for Nephrology
- Target Recruit Count
- 150
- Registration Number
- NCT00373165
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
- Conditions
- Cytomegalovirus Infections
- Interventions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT00372229
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.